Cure of gonococcal infection (microbiological culture) · pregnant women with gonorrhoea infection
It is very uncertain whether intramuscular ceftriaxone changes cure of gonococcal infection (microbiological culture) compared with oral amoxicillin plus oral probenecid (very low certainty).
1 finding from 1 review
Incidence of obstetric complications · pregnant women with gonorrhoea infection
1 finding from 1 review
Incidence of disseminated gonococcal infection · pregnant women with gonorrhoea infection
1 finding from 1 review
Neonatorum ophthalmia · pregnant women with gonorrhoea infection
1 finding from 1 review
Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection
It is very uncertain whether intramuscular ceftriaxone changes adverse events including treatment‐related adverse events compared with oral amoxicillin plus oral probenecid (very low certainty).
1 finding from 1 review
All‐cause mortality · NSTI
It is very uncertain whether moxifloxacin changes mortality compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to higher response rate ‐ microbiological response compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
It is very uncertain whether fluoroquinolones changes response rate ‐ improvement in sputum purulence (excellent) compared with amoxicillin (very low certainty).
1 finding from 1 review
Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found